EGFR and lung carcinoma: Moreover, mutations in EGFR kinase domain have been shown to mediate STAT3 activation by IL-6 production in human lung carcinomas (Gao et al, 2007), suggesting that EGFR-like STAT3 activation can be mediated by IL-6R or GP130 receptors in an autocrine manner.